Novel Risk Scoring System for Immune Checkpoint Inhibitors Treatment in Non-Small Cell Lung Cancer

Chuling Li; Meiqi Shi; Xinqing Lin; Yongchang Zhang; Shaorong Yu; Chengzhi Zhou; Nong Yang; Jianya Zhang; Fang Zhang; Tangfeng Lv; Hongbing Liu; Yong Song

Disclosures

Transl Lung Cancer Res. 2021;10(2):776-789. 

In This Article

Conclusions

Thus, the LEM score is a novel risk scoring system consisting of ALC (L), ECOG PS (E), and lung/pleural metastasis (M). It could act as a potential prognostic biomarker of ORR and PFS for patients treated with ICIs in NSCLC. Further large-sample studies are required to externally validate the LEM score.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....